U.S. Food and Drug Administration (FDA) · United States

FDA Off-Label Promotion - Digital and HCP Communication Risks

Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.

21 U.S.C. 352(a), (f); 21 CFR 202.1; FDA SIUU Q&A Guidance (Jan. 2025)

What is FDA Off-Label Promotion - Digital and HCP Communication Risks?

Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion. Apply to US reprints, study summaries and digital resources on unapproved uses that drug and device firms share with HCPs.

US Federal

Read official source

Last reviewed: 2026-11-05

General information, not legal advice.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug, Medical Device · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-05-10

What does this rule require?

Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.

How can marketing teams comply?

Apply to US reprints, study summaries and digital resources on unapproved uses that drug and device firms share with HCPs.

Where can I read the official source?

Read official source

Key facts

Regulatory authority
U.S. Food and Drug Administration (FDA)
Jurisdiction
United States
Official citation
21 U.S.C. 352(a), (f); 21 CFR 202.1; FDA SIUU Q&A Guidance (Jan. 2025)
Published
2026-11-16
Effective date
2026-05-10
Channel
all_channels
Products
Prescription Drug, Medical Device
Audiences
general_audience, general_adults_18plus, customers, health_professionals

Frequently asked questions

What is FDA Off-Label Promotion - Digital and HCP Communication Risks?

Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug, Medical Device · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-05-10

Request a free compliance scan of your homepage and book a time with Warrant.

Get a free homepage compliance scan